Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses INBX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named INBX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mark Lappe | $695,250 | $1,700,000 | $0 | $0 | $479,723 | $0 | $17,500 | $2,892,473 |
| Chief Executive Officer and Chairman of the Board of Directors | ||||||||
| David Matly | 589,170 | 0 | 0 | 524,285 | 304,985 | 0 | 17,500 | 1,435,940 |
| President | ||||||||
| Kelly Deck | 493,485 | 0 | 0 | 157,286 | 255,425 | 0 | 17,500 | 923,696 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Mark Lappe | $2,892,473 | $4,691,783 | — | −1,799,310 |
| David Matly | 1,435,940 | — | — | — |
| Kelly Deck | 923,696 | 4,267,254 | — | −3,343,558 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| David Matly | President | 2026-04-24 | A | 50,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Kristiina Vuori MD | Director | 2026-06-03 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jon Faiz Kayyem | Director | 2026-06-03 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Douglas G. Forsyth | Director | 2026-06-03 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kimberly Manhard | Director | 2026-06-03 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| David Matly | OPTION | — | — | — | — | — | $524,285 |
| Kelly Deck | OPTION | — | — | — | — | — | 157,286 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| David Matly | $0 | $0 | $524,285 | 0.0% |
| Kelly Deck | 0 | 0 | 157,286 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Matly | Option | 50,000 | 14.05 | — |
| David Matly | Option | 105,729 | 15.86 | — |
| David Matly | Option | 3,500,855 | 16.06 | — |
| Mark Lappe | Option | 181,250 | 15.86 | — |
| Kelly Deck | Option | 105,729 | 15.86 | — |
| Kelly Deck | Option | 15,000 | 14.05 | — |
equity grants provide our executive officers with a strong link to our long-term performance, create an ownership opportunity, and help to align the interests of our executive officers and our stockholders
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Douglas G. ForsythIndependent · Audit (Chair) · Compensation · Nominating/Governance (Chair) | $63,000 | $0 | $139,685 | $0 | $0 | $202,685 |
| Jon Faiz Kayyem, Ph.DIndependent · Audit · Compensation (Chair) | 52,500 | 0 | 139,685 | 0 | 0 | 192,185 |
| Kristiina Vuori, M.D., Ph.DIndependent · Audit · Nominating/Governance | 46,500 | 0 | 139,685 | 0 | 0 | 186,185 |
| Kimberly ManhardIndependent · Compensation · Nominating/Governance | 44,000 | 0 | 139,685 | 0 | 0 | 183,685 |
| Mark P. LappeEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $35,000 |
|---|---|
| Annual equity retainer | $139,685 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $206,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $206,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Inhibrx Biosciences, Inc. | 2025 | Mark Lappe | $695,250 | $0 | $0 | $479,723 | $2,892,473 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Mark Lappe | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Summary Compensation Table” · page 16. As printed: 2,892,473. Filing ↗machine: span 234894–234903 |
| 2 | Section 01, David Matly | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Summary Compensation Table” · page 16. As printed: 1,435,940. Filing ↗machine: span 252124–252133 |
| 3 | Section 01, Kelly Deck | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Summary Compensation Table” · page 16. As printed: 923,696. Filing ↗machine: span 243449–243456 |
| 4 | Section 03, David Matly OPTION | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t15 · r6 · c13 · span 250289–250296 |
| 5 | Section 03, Kelly Deck OPTION | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t15 · r4 · c13 · span 241614–241621 |
| 6 | Section 07, pay ratio | 10-K | 2026-03-19 | 0002007919-26-000006 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 7 | Section 08, Douglas G. Forsyth | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Director Compensation”. As printed: 202,685. Filing ↗machine: t12 · r2 · c15 · span 195699–195706 |
| 8 | Section 08, Jon Faiz Kayyem, Ph.D | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Director Compensation”. As printed: 192,185. Filing ↗machine: t12 · r3 · c15 · span 198527–198534 |
| 9 | Section 08, Kristiina Vuori, M.D., Ph.D | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Director Compensation”. As printed: 186,185. Filing ↗machine: t12 · r5 · c15 · span 204127–204134 |
| 10 | Section 08, Kimberly Manhard | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Director Compensation”. As printed: 183,685. Filing ↗machine: t12 · r4 · c15 · span 201321–201328 |
| 11 | Section 08, Mark P. Lappe | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 02, David Matly 2026-04-24 | Form 4 | 2026-04-27 | 0002062665-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 13 | Section 02, Kristiina Vuori MD 2026-06-03 | Form 4 | 2026-06-04 | 0001612627-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 14 | Section 02, Jon Faiz Kayyem 2026-06-03 | Form 4 | 2026-06-04 | 0001366268-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 15 | Section 02, Douglas G. Forsyth 2026-06-03 | Form 4 | 2026-06-04 | 0001240801-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Kimberly Manhard 2026-06-03 | Form 4 | 2026-06-04 | 0001202094-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 18 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 19 | Section 09b board cost (computed) | Computed | — | computed | Cash 206,000 + equity 0 + all other 0 = 206,000, summed across the director compensation table rows.machine: formula: Σ = 206,000 |
| 20 | Inhibrx Biosciences, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-23 | 0002007919-26-000014 | CEO total compensation as printed in Inhibrx Biosciences, Inc.'s own proxy. As printed: 2,892,473. Filing ↗machine: span 234894–234903 |